Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
COL8A2 CRISPR Activation Plasmid (h): sc-403831-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- COL8A2 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- COL8A2 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by COL8A2 CRISPR Activation Plasmid (h) and COL8A2 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the COL8A2 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: COL8A2 Antibody (1F4): sc-293350
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
COL8A2 CRISPR Activation Plasmid (h) | sc-403831-ACT | 20 µg | $397.00 |
COL8A2 encodes the alpha 2 chain of type VIII collagen, a non-fibrillar short-chain collagen that contributes to extracellular matrix organization and basement membrane-associated structures. In ocular tissues it is enriched in corneal endothelium and Descemet’s membrane, where it supports matrix assembly, cell adhesion, and biomechanical integrity. COL8A2-associated matrix remodeling interfaces with pathways governing cell–matrix signaling, including integrin-mediated adhesion and extracellular matrix turnover. Genetic variation or dysregulated expression of COL8A2 has been linked to corneal endothelial dystrophies, making it a relevant target for studying extracellular matrix homeostasis and endothelial cell function.
COL8A2 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous COL8A2 expression without altering the underlying DNA sequence.
COL8A2 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the COL8A2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the COL8A2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous COL8A2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native COL8A2 locus and enabling the study of COL8A2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of COL8A2 pathway restoration in tumor cells with silenced or reduced COL8A2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.